Merck
  • Home
  • Search Results
  • Azithromycin, Ureaplasma and chronic lung disease of prematurity: a case study for neonatal drug development.

Azithromycin, Ureaplasma and chronic lung disease of prematurity: a case study for neonatal drug development.

Archives of disease in childhood (2011-06-24)
Mark A Turner, Evelyne Jacqz-Aigrain, Sailesh Kotecha
ABSTRACT

Chronic lung disease of prematurity (CLD) remains a major cause of morbidity and mortality in preterm infants. Ureaplasma has received intermittent attention over the last two decades as a possible contributory factor. In addition, pulmonary inflammation is associated with the development of CLD. The macrolide azithromycin provides an attractive option to determine if it can decrease the development of CLD as it has both anti-inflammatory and anti-infective properties. In this article, the authors review the evidence for the role of Ureaplasma in the development of CLD and the obstacles faced in the development of a drug before it reaches clinical practice.

MATERIALS
Product Number
Brand
Product Description

Supelco
Azithromycin, Pharmaceutical Secondary Standard; Certified Reference Material
USP
Azithromycin, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Azithromycin dihydrate, ≥98% (HPLC)